종양용해성 바이러스 면역요법 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Oncolytic Virus Immunotherapy Market size is expected to reach USD 3167.20 Million in 2034 from USD 490.79 Million (2025) growing at a CAGR of 23.02% during 2026-2034.

The global oncolytic virus immunotherapy market is gaining momentum due to the increasing demand for innovative cancer treatment solutions. Oncolytic viruses selectively infect and destroy cancer cells while stimulating the immune system, making them a promising therapeutic approach. The rising prevalence of cancer and the growing focus on targeted therapies are key factors driving market growth. Additionally, advancements in biotechnology and immunotherapy are supporting the development of novel oncolytic virus treatments.

Key growth drivers include increasing investments in cancer research and the growing number of clinical trials focused on immunotherapy. The shift toward personalized medicine and combination therapies is also contributing to market expansion. Collaborations between pharmaceutical companies and research institutions are accelerating innovation and commercialization. Furthermore, regulatory support and fast-track approvals for advanced therapies are boosting market development.

In the future, the oncolytic virus immunotherapy market is expected to witness substantial growth as more therapies progress through clinical trials and receive approval. Technological advancements in genetic engineering will enhance the efficacy and safety of these treatments. Emerging markets are likely to offer significant growth opportunities due to improving healthcare infrastructure and rising cancer awareness. Additionally, ongoing research will continue to expand the potential applications of oncolytic virus therapies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Virus Type

• Herpes Simplex Virus (HSV)
• Adenovirus
• Vaccinia Virus
• Newcastle Disease Virus
• Reovirus
• Other Virus Types

By Route of Administration

• Intratumoral
• Intravenous
• Other Routes of Administration

By Application

• Melanoma
• Breast Cancer
• Lung Cancer
• Ovarian Cancer
• Prostate Cancer
• Other Applications

By End-User

• Hospitals & Clinics
• Cancer Research Institutes
• Ambulatory Surgical Centers
• Other End-Users

COMPANIES PROFILED

• Amgen Inc, Creative Biolabs, Daiichi Sankyo Company Limited, Genelux Corporation, Oncorus Inc, Replimune Group Inc, SIGA Technologies Inc, Sorrento Therapeutics Inc, TILT Biotherapeutics Ltd, Viralytics Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET: BY VIRUS TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Virus Type
• 4.2. Herpes Simplex Virus (HSV) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Adenovirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vaccinia Virus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Newcastle Disease Virus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Reovirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Other Virus Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Intratumoral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Other Routes of Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Ovarian Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET: BY END-USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-user
• 7.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Cancer Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Ambulatory Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Other End-Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Virus Type
  • 8.2.2 By Route Of Administration
  • 8.2.3 By Application
  • 8.2.4 By End-user
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Virus Type
  • 8.3.2 By Route Of Administration
  • 8.3.3 By Application
  • 8.3.4 By End-user
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Virus Type
  • 8.4.2 By Route Of Administration
  • 8.4.3 By Application
  • 8.4.4 By End-user
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Virus Type
  • 8.5.2 By Route Of Administration
  • 8.5.3 By Application
  • 8.5.4 By End-user
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Virus Type
  • 8.6.2 By Route Of Administration
  • 8.6.3 By Application
  • 8.6.4 By End-user
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Amgen Inc
  • 10.2.2 Creative Biolabs
  • 10.2.3 Daiichi Sankyo Company Limited
  • 10.2.4 Genelux Corporation
  • 10.2.5 Oncorus Inc
  • 10.2.6 Replimune Group Inc
  • 10.2.7 SIGA Technologies Inc
  • 10.2.8 Sorrento Therapeutics Inc
  • 10.2.9 TILT Biotherapeutics Ltd
  • 10.2.10 Viralytics Ltd